Photo: Depositphotos
Aug 6, 2025, 08:52
Ahmed Kotb: First Line Management of Stage III-IV DLBCL
Ahmed Kotb, Adult Hematology and Bone Marrow Transplant Specialist at King Faisal Specialist Hospital International Holding Company, shared a post on X:
“ESMO 2025 – Stage III-IV DLBCL
PET+ test MYC ± BCL2
<80, fit:
- IPI <2 → 6x R-CHOP
- IPI ≥2 → 6x R-Pola-CHP
≥80 or unfit:
- Fit: R-miniCHOP
- Unfit: R-COMP / R-GCVP / R-CEOP
Consider ISRT for bulky/residual and CNS ppx if high-risk.”
More posts featuring DLBCL.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 6, 2025, 22:57
Aug 6, 2025, 22:41
Aug 6, 2025, 22:14
Aug 6, 2025, 21:48
Aug 6, 2025, 21:33
Aug 6, 2025, 21:22
Aug 6, 2025, 21:13